The novel sigma-2 receptor ligand SW43 stabilizes pancreas cancer progression in combination with gemcitabine.
about
Siramesine triggers cell death through destabilisation of mitochondria, but not lysosomes4-aroylpiperidines and 4-(α-hydroxyphenyl)piperidines as selective sigma-1 receptor ligands: synthesis, preliminary pharmacological evaluation and computational studiesConjugation to a SMAC mimetic potentiates sigma-2 ligand induced tumor cell death in ovarian cancerThe σ2 receptor: a novel protein for the imaging and treatment of cancer.Targeted pancreatic cancer therapy with the small molecule drug conjugate SW IV-134.Using SV119-gold nanocage conjugates to eradicate cancer stem cells through a combination of photothermal and chemo therapies.Identification of the PGRMC1 protein complex as the putative sigma-2 receptor binding site.Sigma-2 receptor ligands and their perspectives in cancer diagnosis and therapy.Fluorescent derivatives of σ receptor ligand 1-cyclohexyl-4-[3-(5-methoxy-1,2,3,4-tetrahydronaphthalen-1-yl)propyl]piperazine (PB28) as a tool for uptake and cellular localization studies in pancreatic tumor cells.Characterization of interactions of 4-nitrophenylpropyl-N-alkylamine with ς receptors.Use of multifunctional sigma-2 receptor ligand conjugates to trigger cancer-selective cell death signalingLysosomal membrane permeabilization is an early event in Sigma-2 receptor ligand mediated cell death in pancreatic cancer.Sigma-2 receptor agonist derivatives of 1-Cyclohexyl-4-[3-(5-methoxy-1,2,3,4-tetrahydronaphthalen-1-yl)propyl]piperazine (PB28) induce cell death via mitochondrial superoxide production and caspase activation in pancreatic cancer.The Sigma-2 Receptor and Progesterone Receptor Membrane Component 1 are Different Binding Sites Derived From Independent Genes.The sigma-2 receptor as a therapeutic target for drug delivery in triple negative breast cancer.Progesterone Receptor Membrane Component 1 (PGRMC1) Expression in Murine RetinaSW43-DOX ± loading onto drug-eluting bead, a potential new targeted drug delivery platform for systemic and locoregional cancer treatment - An in vitro evaluationConjugation to the sigma-2 ligand SV119 overcomes uptake blockade and converts dm-Erastin into a potent pancreatic cancer therapeutic.Neuroprotective targets through which 6-acetyl-3-(4-(4-(4-fluorophenyl)piperazin-1-yl)butyl)benzo[d]oxazol-2(3H)-one (SN79), a sigma receptor ligand, mitigates the effects of methamphetamine in vitro.Therapeutic targeting of pancreatic cancer utilizing sigma-2 ligands.Intelligent design of multifunctional lipid-coated nanoparticle platforms for cancer therapy.The Evolution of the Sigma-2 (σ2) Receptor from Obscure Binding Site to Bona Fide Therapeutic Target.Progesterone receptor membrane component 1/Sigma-2 receptor associates with MAP1LC3B and promotes autophagy.2-Aminopyridine derivatives as potential σ(2) receptor antagonists.SV119-gold nanocage conjugates: a new platform for targeting cancer cells via sigma-2 receptorsSigma1 Pharmacology in the Context of Cancer.Functional N-Formyl Peptide Receptor 2 (FPR2) Antagonists Based on the Ureidopropanamide Scaffold Have Potential To Protect Against Inflammation-Associated Oxidative Stress.Multifunctional thiosemicarbazones and deconstructed analogues as a strategy to study the involvement of metal chelation, Sigma-2 (σ2) receptor and P-gp protein in the cytotoxic action: In vitro and in vivo activity in pancreatic tumors.Sigma Receptor (σR) Ligands with Antiproliferative and Anticancer Activity.
P2860
Q28390864-55443738-3ED6-406D-B568-3B1ED62AB30DQ28829344-1AF5E94F-FEE6-4089-BF85-0E46D939C9F2Q33589984-6DE5E89F-BAC3-4B0F-924B-BC9546039F5BQ33782364-AAE03535-36F2-4E0B-A437-D43DF63F6D1CQ33849311-DBB19665-0204-4A53-8C46-F186A5929CA5Q34052669-D9DB811D-BD59-4E3E-A87F-CE38118C6F72Q34197697-0C084294-2950-4B35-BAA0-8029E8409599Q34362333-8CF68BA3-EE82-4774-8D24-39EB4055F1B6Q35234944-647FE423-D069-42D2-AE44-D5981FD86B87Q35602646-029CEC30-0F99-4E9A-BD4C-E1E079BAEA91Q35652832-EB1ECB6A-FE93-485A-9C5A-83133931E328Q36150331-C78249BE-A970-4F0F-B80E-8EBF11960882Q36249357-0A9E9D9D-4534-4E50-8B64-865AFA8BC27EQ36540952-C899C676-F38C-4C23-92A8-DBEDDA0CF59CQ36551212-022EAC63-B95D-4963-9E3C-43397689A7DAQ36978618-66391C4A-1BBA-44B0-861D-EA97CBBA9C8CQ37150075-FD0292FE-BBBA-4CD8-B081-AC97ECD5DE17Q37376094-73A0FA20-939F-4A02-9744-C730837675A7Q37714283-CFC6B457-FD4F-4785-9CDE-D69CDD4AC6C7Q38024011-FA020657-DEB3-45FF-BFB6-B33382FBBF2CQ38074442-C54CBA51-489C-4817-9A86-35AA0C0C0FB3Q38896673-C56B3DDA-9D33-402B-A9CF-9E5438429C1AQ39082987-94E71D99-FB91-4D6C-9198-D7FC672AAA72Q39297889-0538E284-8353-4DEB-BA8F-D3C5E9D20254Q39437911-232A1B4B-ECA6-4FC5-B686-0EA53D4E4C2DQ39458668-043FB7FB-4492-4F41-8743-167AB5D429F5Q46305001-6B16C7DC-A188-4098-8128-0A1923E10EF7Q47245050-D5A4646F-83D8-43C8-A38E-2B6FC9950C12Q52757903-290A6E50-E804-4240-9BF4-923EA8CFAD7C
P2860
The novel sigma-2 receptor ligand SW43 stabilizes pancreas cancer progression in combination with gemcitabine.
description
2010 nî lūn-bûn
@nan
2010 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
The novel sigma-2 receptor lig ...... combination with gemcitabine.
@ast
The novel sigma-2 receptor lig ...... combination with gemcitabine.
@en
type
label
The novel sigma-2 receptor lig ...... combination with gemcitabine.
@ast
The novel sigma-2 receptor lig ...... combination with gemcitabine.
@en
prefLabel
The novel sigma-2 receptor lig ...... combination with gemcitabine.
@ast
The novel sigma-2 receptor lig ...... combination with gemcitabine.
@en
P2093
P2860
P356
P1433
P1476
The novel sigma-2 receptor lig ...... n combination with gemcitabine
@en
P2093
Dirk Spitzer
John R Hornick
Peter Goedegebuure
Robert H Mach
Suwanna Vangveravong
William G Hawkins
P2860
P2888
P356
10.1186/1476-4598-9-298
P577
2010-11-22T00:00:00Z
P5875
P6179
1034471699